Q1 Earnings Estimate for NTLA Issued By William Blair
Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter anticipates ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
GEN - Genetic Engineering and Biotechnology News12h
StockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.?
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...